Corcept Therapeutics Incorporated (CORT)
| Market Cap | 4.46B -26.0% |
| Revenue (ttm) | 761.41M +12.8% |
| Net Income | 98.17M -29.4% |
| EPS | 0.82 -33.3% |
| Shares Out | 106.37M |
| PE Ratio | 51.11 |
| Forward PE | 103.23 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 843,252 |
| Open | 42.34 |
| Previous Close | 42.25 |
| Day's Range | 41.45 - 42.81 |
| 52-Week Range | 28.66 - 91.00 |
| Beta | 0.25 |
| Analysts | Buy |
| Price Target | 96.50 (+130.26%) |
| Earnings Date | May 4, 2026 |
About CORT
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortis... [Read more]
Financial Performance
In 2025, Corcept Therapeutics's revenue was $761.41 million, an increase of 12.79% compared to the previous year's $675.04 million. Earnings were $98.17 million, a decrease of -29.74%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for CORT stock is "Buy." The 12-month stock price target is $96.5, which is an increase of 130.26% from the latest price.
News
Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer
Corcept Therapeutics shares jumped more than 32% to nearly a two-month high on Wednesday after the U.S. health regulator approved its lead drug for treating an aggressive form of ovarian cancer that...
FDA Approves Corcept's Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Shareholders who lost money in shares of Corcept Therapeutics (NASDAQ: CORT) should contact Wolf Haldenstein immediately
Lead Plaintiff Deadline is April 21, 2026 NEW YORK, March 24, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed aga...
Robbins LLP Urges CORT Stockholders to Contact the Firm for Information About the Class Against Corcept Therapeutics Incorporated
SAN DIEGO, March 18, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Corcept Therapeutics Incorporate...
Corcept Therapeutics Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, March 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Corcept Therapeutics Incorporated (NASDAQ: CORT). The investigation focus...
REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026
NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP reminds Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ:CORT) investors of the April 21, 2026 deadline to seek the role of lead pl...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 21, 2026 in Corcept Therapeutics Incorporated Lawsuit - CORT
NEW YORK, March 10, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT). Shareholders who purchased shares of CORT d...
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics Stock Plunges As Court Clears Teva Generic
Corcept had argued that Teva's label for its generic version of Korlym, a drug used to treat Cushing's syndrome, would induce doctors to follow patented dosing methods involving mifepristone and stron...
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2025 financial results and provide a corporate updat...
CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
LOS ANGELES, Feb. 09, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeut...
Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT
LOS ANGELES, Feb. 9, 2026 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: ...
Corcept Therapeutics (CORT) Shares Fall Again Amid Report FDA Warned Several Times Not to Submit Relacorilant Drug Application – Hagens Berman
SAN FRANCISCO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- The latest adverse development for Corcept Therapeutics (NASDAQ: CORT) concerning its proposed treatment of patients with hypercortisolism (also known ...
Hagens Berman Investigating Corcept Therapeutics (CORT): Shares Fall After Report That FDA Warned Against Relacorilant Drug Application Filing
SAN FRANCISCO--(BUSINESS WIRE)--Hagens Berman, a national shareholder rights law firm, is investigating whether Corcept Therapeutics Inc. (NASDAQ: CORT) misled investors about relacorilant's efficacy ...
Berman Tabacco Announces Investigation of Corcept Therapeutics Incorporated (NASDAQ: CORT) Concerning FDA New Drug Application
BOSTON, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Berman Tabacco, a national law firm representing investors, announces that it is investigating potential securities law violations by Corcept Therapeutics Inc...
Corcept shares tumble after FDA letter reveals warnings before drug rejection
Shares of Corcept Therapeutics fell 16% on Friday after a corrected "complete response letter" from the U.S. Food and Drug Administration showed the agency had warned the company "on several occasion...
Corcept Therapeutics Investigated for Securities Fraud Following Report of FDA Warnings; Shareholders Should Contact Block & Leviton To Recover Losses
BOSTON, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Corcept Therapeutics Inc. (Nasdaq: CORT) for potential securities law violations. Investors who have lost money in their Corc...
Corcept Therapeutics Experimental Lead Drug Cuts Death Risk By 35% In Advanced Ovarian Cancer Patients, Stock Jumps
Corcept Therapeutics Incorporated (NASDAQ: CORT) stock is trading higher on Thursday, with a session volume of 3.06 million.
Corcept's cancer drug meets main goal in late-stage trial
Corcept Therapeutics said on Thursday that its experimental cancer drug met the main goal in a late-stage study.
Overall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...
Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – CORT
LOS ANGELES--(BUSINESS WIRE)--Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – CORT.